These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27271656)

  • 1. Malignant Mesothelioma and Delivery of Polyphenols.
    Bishop KS; Braakhuis AJ; Ferguson LR
    Nutrients; 2016 Jun; 8(6):. PubMed ID: 27271656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.
    Estrela JM; Mena S; Obrador E; Benlloch M; Castellano G; Salvador R; Dellinger RW
    J Med Chem; 2017 Dec; 60(23):9413-9436. PubMed ID: 28654265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.
    Pulito C; Mori F; Sacconi A; Casadei L; Ferraiuolo M; Valerio MC; Santoro R; Goeman F; Maidecchi A; Mattoli L; Manetti C; Di Agostino S; Muti P; Blandino G; Strano S
    Oncotarget; 2015 Jul; 6(20):18134-50. PubMed ID: 26136339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phytochemicals in Malignant Pleural Mesothelioma Treatment-Review on the Current Trends of Therapies.
    Chmielewska-Kassassir M; Wozniak LA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol and cisplatin in a malignant mesothelioma cell model.
    Chirumbolo S; Bjørklund G
    Food Chem Toxicol; 2016 Dec; 98(Pt B):308-309. PubMed ID: 27856297
    [No Abstract]   [Full Text] [Related]  

  • 6. A case report of peritoneal malignant mesothelioma presenting as primary ovarian mass.
    Kapoor R; Kuttikat PG; Vaiphei K; Rai B; Patel FD
    J Cancer Res Ther; 2015; 11(3):654. PubMed ID: 26458642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
    Yamazoe M; Ozasa H; Kim YH
    J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
    Blomberg C; Nilsson J; Holgersson G; Edlund P; Bergqvist M; Adwall L; Ekman S; Brattström D; Bergström S
    Anticancer Res; 2015 May; 35(5):2493-501. PubMed ID: 25964522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus aureus bio-products: new biological roles for a pleurodesis agent.
    Psallidas I; Stathopoulos GT
    Respirology; 2014 Oct; 19(7):948-9. PubMed ID: 25139703
    [No Abstract]   [Full Text] [Related]  

  • 10. Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
    McCusker MG; Scilla KA; Simone CB; Sachdeva A; Miller KD; Burke AP; Rolfo C
    J Thorac Oncol; 2019 Sep; 14(9):e185-e187. PubMed ID: 31235402
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical features of patients with malignant peritoneal mesothelioma initially presenting as a local inflammation].
    Song H; Zheng G; Wei S; Yang Y; Wei X
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):312-3. PubMed ID: 24989921
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.
    Agatsuma N; Yasuda Y; Ozasa H
    J Thorac Oncol; 2017 Sep; 12(9):e141-e143. PubMed ID: 28838714
    [No Abstract]   [Full Text] [Related]  

  • 13. IASLC 2020 World Conference on Lung Cancer.
    Venkatesan P
    Lancet Respir Med; 2020 Oct; 8(10):e76. PubMed ID: 32866439
    [No Abstract]   [Full Text] [Related]  

  • 14. Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.
    Liu R; Colby AH; Gilmore D; Schulz M; Zeng J; Padera RF; Shirihai O; Grinstaff MW; Colson YL
    Biomaterials; 2016 Sep; 102():175-86. PubMed ID: 27343465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine deprivation for ASS1-deficient mesothelioma.
    Burki TK
    Lancet Oncol; 2016 Oct; 17(10):e423. PubMed ID: 27622996
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
    Buikhuisen WA; Qayyum F; Armato SG; Baas P
    Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
    [No Abstract]   [Full Text] [Related]  

  • 17. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
    Belani CP; Adak S; Aisner S; Stella PJ; Levitan N; Johnson DH;
    Clin Lung Cancer; 2004 Jul; 6(1):43-7. PubMed ID: 15310416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in Malignant Pleural Mesothelioma.
    Oehl K; Vrugt B; Opitz I; Meerang M
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Dilemma: Primary Peritoneal Mesothelioma With Para-Occupational Asbestos Exposure.
    Qin KR; Dua D
    J Glob Oncol; 2017 Dec; 3(6):828-832. PubMed ID: 29244982
    [No Abstract]   [Full Text] [Related]  

  • 20. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
    Wang Y; Jiang Z; Yan J; Ying S
    Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.